• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV (Amendment)

    5/10/24 4:31:19 PM ET
    $ARYD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARYD alert in real time by email
    SC 13G/A 1 aryd20240430.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
     
     

    ARYA SCIENCES ACQUISITION CORP IV

    (Name of Issuer)
     

    Class A Ordinary Share, $0.0001 par value per share

    (Title of Class of Securities)
     

    G31659108

    (CUSIP Number)
     

    April 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Glazer Capital, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    240,233

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    240,233

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    240,233

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.32%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     
     

     

     

    1

    NAME OF REPORTING PERSON

    Paul J. Glazer

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    240,233

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    240,233

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    240,233

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.32%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     
     

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is ARYA SCIENCES ACQUISITION CORP IV (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 51 Astor Place, 10th Floor, New York, NY 10003.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and
       
      (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds.
       
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.

     

    Item 2(c). CITIZENSHIP:
       
      Glazer Capital is a Delaware limited liability company.  Mr. Glazer is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Class A Ordinary Share, $0.0001 par value per share

     

    Item 2(e). CUSIP NUMBER:
       
      G31659108

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     
     

     

      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨

    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ¨

    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

      (e) ý

    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ý

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨

    Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentages set forth in Row (11) of the cover page for each Reporting Person and elsewhere in this Schedule 13G/A are based on the 3,799,016 shares of Class A Ordinary Share, $0.0001 par value per share, based upon the Company's Form 10-K filing dated March 28, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
     
     

     

       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its or his knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: May 10, 2024

     

    GLAZER CAPITAL, LLC    
         
         
    By: /s/ Paul J. Glazer    
    Name: Paul J. Glazer    
    Title: Managing Member    
         
         
    /s/ Paul J. Glazer    
    PAUL J. GLAZER    

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $ARYD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARYD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ARYD
    SEC Filings

    See more
    • SEC Form 15-12G filed by ARYA Sciences Acquisition Corp IV

      15-12G - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)

      8/12/24 4:30:11 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 25-NSE filed by ARYA Sciences Acquisition Corp IV

      25-NSE - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      7/31/24 5:16:44 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)

      7/26/24 4:30:22 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ARYD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV

      SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      6/28/24 5:09:55 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV (Amendment)

      SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      5/10/24 4:31:19 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by ARYA Sciences Acquisition Corp IV

      SC 13G - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)

      2/14/24 3:30:36 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Stone Adam Leo returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:52:23 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Henderson Michael Thomas

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:49:31 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Trigg Leslie

      4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)

      7/31/24 9:46:16 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Financials

    Live finance-specific insights

    See more
    • Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: "Caritas Therapeutics"

      Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Global Commercialization and Late Stage Product Development Biotechnology Company in Rare Diseases Transaction Advances Amicus Path to Profitability - Expected as of 2023 Amicus Balance Sheet Further Strengthened with a ~$200M Private Investment from Leading Biotechnology Investors Separation will Sharpen the Strategic Focus, Financial Profile, and Operational Execution of Both Companies to Address the Needs of People Living with Rare Diseases – A

      9/29/21 6:30:00 AM ET
      $ARYD
      $FOLD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ARYD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adagio Medical Provides Business Updates

      Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug Administration ("FDA") approval for the FULCRUM-VT Pivotal IDE study Cl

      8/19/24 4:01:00 PM ET
      $ADGM
      $ARYD
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias

      Business combination transaction with ARYA Sciences Acquisition Corp IV, a special purpose acquisition company sponsored by an affiliate of Perceptive Advisors, closed on July 31, 2024 Publicly traded company renamed Adagio Medical Holdings, Inc., with Adagio Medical as an operating subsidiary Common stock expected to commence trading under ticker symbol "ADGM" on the Nasdaq Capital Market on August 1, 2024 Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD, or "ARYA IV"))), a special purpos

      7/31/24 4:01:00 PM ET
      $ARYD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARYD
    Leadership Updates

    Live Leadership Updates

    See more
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care